JP2012516899A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516899A5
JP2012516899A5 JP2011549263A JP2011549263A JP2012516899A5 JP 2012516899 A5 JP2012516899 A5 JP 2012516899A5 JP 2011549263 A JP2011549263 A JP 2011549263A JP 2011549263 A JP2011549263 A JP 2011549263A JP 2012516899 A5 JP2012516899 A5 JP 2012516899A5
Authority
JP
Japan
Prior art keywords
compound
hydrogen
halogen
composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011549263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516899A (ja
JP5653939B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023220 external-priority patent/WO2010091193A2/en
Publication of JP2012516899A publication Critical patent/JP2012516899A/ja
Publication of JP2012516899A5 publication Critical patent/JP2012516899A5/ja
Application granted granted Critical
Publication of JP5653939B2 publication Critical patent/JP5653939B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011549263A 2009-02-05 2010-02-04 抗癌剤および免疫調節因子としてのトリプトリドc環誘導体 Expired - Fee Related JP5653939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15020709P 2009-02-05 2009-02-05
US61/150,207 2009-02-05
PCT/US2010/023220 WO2010091193A2 (en) 2009-02-05 2010-02-04 Triptolide c-ring derivatives as anticancer agents and immune modulators

Publications (3)

Publication Number Publication Date
JP2012516899A JP2012516899A (ja) 2012-07-26
JP2012516899A5 true JP2012516899A5 (enExample) 2013-02-21
JP5653939B2 JP5653939B2 (ja) 2015-01-14

Family

ID=42542652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549263A Expired - Fee Related JP5653939B2 (ja) 2009-02-05 2010-02-04 抗癌剤および免疫調節因子としてのトリプトリドc環誘導体

Country Status (7)

Country Link
US (1) US8268882B2 (enExample)
EP (1) EP2393818A4 (enExample)
JP (1) JP5653939B2 (enExample)
CN (2) CN102307881B (enExample)
AU (1) AU2010210594B2 (enExample)
CA (1) CA2750844A1 (enExample)
WO (1) WO2010091193A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480040B (zh) * 2012-06-11 2015-04-11 Univ Kaohsiung Medical 雷公藤甲素用於製備治療與運動神經元存活蛋白質表現相關之疾病的藥物的用途
WO2014031979A1 (en) 2012-08-23 2014-02-27 Dyer, Cheryl, A. Reducing the reproductive capacity of mammals

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
CN1027371C (zh) * 1989-09-08 1995-01-11 中国医学科学院皮肤病研究所 二萜内酯化合物的合成方法
AU7570191A (en) 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
NZ500762A (en) * 1997-05-23 2001-08-31 Aventis Pharma Inc Triptolide derivatives substituted with amino acids, useful in the treatment of autoimmune diseases
US6004999A (en) * 1997-05-23 1999-12-21 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
EP1109789B1 (en) * 1998-09-02 2003-07-16 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
JP2001081030A (ja) * 1999-07-13 2001-03-27 Mitsuhiro Hatta 免疫抑制剤の副作用防御剤
WO2002017931A1 (fr) 2000-09-01 2002-03-07 Xiaomin Wang Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
US7847109B2 (en) * 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
JP2004168713A (ja) * 2002-11-20 2004-06-17 St Marianna Univ School Of Medicine アポトーシス誘導剤
CN1726025A (zh) * 2002-12-17 2006-01-25 泛华医药公司 作为免疫调节剂和抗癌剂的雷公藤内酯醇衍生物
CN100408583C (zh) * 2003-02-25 2008-08-06 美国泛华医药公司 用作免疫调节剂和抗癌药的卤代雷公藤内酯醇衍生物
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005000291A1 (en) 2003-06-27 2005-01-06 Pharmagenesis, Inc. Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
US7863464B2 (en) * 2004-03-02 2011-01-04 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
CN100374443C (zh) * 2004-03-29 2008-03-12 北京键凯科技有限公司 亲水性聚合物-雷公藤提取物的结合物及其药物组合物
WO2009023201A1 (en) * 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Similar Documents

Publication Publication Date Title
JP2012144574A5 (enExample)
JP2014508753A5 (enExample)
JP2016537478A5 (enExample)
JP2012532883A5 (enExample)
JP2013542261A5 (enExample)
JP2015528020A5 (enExample)
JP2008195730A5 (enExample)
JP2011227454A5 (enExample)
JP2013508417A5 (enExample)
JP2014501307A5 (enExample)
JP2016074736A5 (enExample)
JP2012512907A5 (enExample)
JP2014515351A5 (enExample)
JP2011207901A5 (enExample)
JP2010174019A5 (enExample)
JP2010501534A5 (enExample)
JP2013032389A5 (enExample)
JP2010254679A5 (ja) トリアゾール誘導体、発光素子、及び発光装置
JP2014510729A5 (enExample)
JP2014097964A5 (enExample)
JP2016515530A5 (enExample)
JP2018538273A5 (enExample)
JP2014513141A5 (enExample)
JP2016530291A5 (enExample)
JP2012254971A5 (ja) カルバゾール化合物